1 / 59

Insulin secretion and resistance (MORE than you ever wanted to know)

Insulin secretion and resistance (MORE than you ever wanted to know). Tisha Joy August 14, 2013. Objectives. Briefly describe insulin secretion and resistance in the context of: Pathophysiology Clinical relevance Assays. Pre-talk Question 1. What is this structure?. Pre-talk question 2.

ova
Télécharger la présentation

Insulin secretion and resistance (MORE than you ever wanted to know)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Insulin secretion and resistance(MORE than you ever wanted to know) Tisha Joy August 14, 2013

  2. Objectives • Briefly describe insulin secretion and resistance in the context of: • Pathophysiology • Clinical relevance • Assays

  3. Pre-talk Question 1 • What is this structure?

  4. Pre-talk question 2 2. Which of the following is correct? A. Insulin consists of 2 chains connected by disulfide bonds B. Proinsulin levels are low in insulinoma C. Insulin has minimal first-pass hepatic clearance D. C-peptide is derived from cleavage of preproinsulin

  5. Pre-talk Question 3 3. All of the following are correct EXCEPT: A. Insulin secretion is normally characterized by 2 phases B. There is loss of the 1st phase of insulin secretion with diabetes C. Pulsatility of insulin secretion is maintained with diabetes D. There is a hyperbolic relationship between insulin secretion and insulin resistance

  6. Pre-question 4 4. Which of the following is CORRECT? A. Development of type 2 diabetes is due to insulin resistance B. Loss of 30% of beta-cell mass leads to diabetes C. Non-diabetic individuals never exhibit insulin resistance D. Insulin resistance occasionally is an adaptive response

  7. Pre-talk Question 5 5. What is the gold standard for determining insulin resistance? A. Insulin tolerance test B. Hyperinsulinemic euglycemic clamp C. Minimal model of FSIVGTT D. HOMA-IR

  8. Background • Beta cells are found in islets of Langerhans, which are variable in size • Normal ~106 islets; total weight 1-2 g; constitute 1-2% of the pancreatic mass www.uptodate.com Image from http://www.vivo.colostate.edu/hbooks/pathphys/endocrine/pancreas/anatomy.html

  9. Background α cells β cells • Beta-cells (70%) – insulin • Alpha cells – glucagon • Delta cells – somatostatin • PP cells – pancreatic polypeptide www.uptodate.com Image from http://www.abpischools.org.uk

  10. Insulin • 51 aa molecule • In portal circulation, insulin concentration is ~200-500pM in fasting state and ~1000-5000 pM in fed state. • Approximately 50-80% of insulin is cleared on 1st pass through the liver. • Estimated basal secretion is 24 units/24 h • T1/2 =10 min Schofield CJ and Sutherland C Diabetic Medicine 2012;29:972-979 Caumo A, Lizio L AJP Endo Metab 2004;287:E371-E385

  11. Insulin synthesis Ribosome Golgi Secretory granules www.uptodate.com

  12. Insulin Insulin synthesis and secretion Glucokinase Adapted from http://www.igis.com Schofield CJ and Sutherland C Diabetic Medicine 2012;29:972-979

  13. 1st phase important in shutting down hepatic glucose production The magnitude of the 1st phase is dependent on the pancreas’ past history of glucose exposure Why important? Preformed De novo Insulin secretion Adapted from Rorsman P et al Physiology 2000;15:72-77 Caumo A and Luzi L Am J Physiol End Metab 2004;287:E371-E385

  14. Multiple players in insulin secretion • Neuropeptide Y • Parasympathetic nervous system + • Incretins • Glucose + + • Activation of K ATP channels • Autocrine Gut - Glucagon Insulin secretion

  15. Insulin secretion Adapted from Rorsman P et al Physiology 2000;15:72-77

  16. Insulin secretion • Individually, β-cells all have differing pulse times (2-5 min), but when formed into aggregates, the pulse rhythm develops into ~4 min cycles • So, the integration of all islets is required to ensure the pancreas releases insulin in a regulated fashion – the integration is mediated by the autonomic nervous system Schofield CJ and Sutherland C Diabetic Medicine 2012;29:972-979

  17. Insulin secretion • Why is pulsatility important? • Maintains the responsiveness of beta-cells to glucose and insulin by preventing the desensitization of the signalling cascade Schofield CJ and Sutherland C Diabetic Medicine 2012;29:972-979

  18. Insulin resistance • Decreased tissue effect of insulin per unit delivered • Hepatic vs. peripheral • In people WITHOUT diabetes or obesity, are there times that they can transiently develop insulin resistance?

  19. Insulin resistance Tsatsoulis A et al Metabolism 2013;62(5):622-633

  20. “Normal” conditions of IR Tsatsoulis A et al Metabolism 2013;62(5):622-633

  21. Sample conditions associated with insulin resistance • Obesity (apple vs. pear) • DM2 • PCOS • Lipodystrophies [familial, acquired (HIV)] Morelet et al JCEM 2006;91:2689-2695

  22. Differences in adipose distribution Control BMI 22.8 Control BMI 34.8 HIV BMI 28.3 Hegele R, Joy T, et al J Lip Res 2007;48:1433-1444

  23. Differences in adipose distribution Muscle Control BMI 22.8 Control BMI 34.8 HIV BMI 28.3 Hegele R, Joy T, et al J Lip Res 2007;48:1433-1444

  24. Insulin resistance Tsatsoulis A et al Metabolism 2013;62(5):622-633

  25. Insulin secretion and resistance are intertwined

  26. Kahn SE et al Diabetes 1993;42(11):1663-1672 http://www.medscape.org/viewarticle/561655

  27. http://www.medscape.org/viewarticle/561655

  28. Butler AE et a Diabetes 2003:52:102-110 http://www.medscape.org/viewarticle/561655

  29. 5.6 – 6.4 6.4 – 8.3 8.3 – 19.4 Brunzell JD et al JCEM 1976;42:222-229 http://www.medscape.org/viewarticle/561655

  30. DM2 • Alterations in insulin secretion in T2DM • Absent 1st-phase insulin response • Reduced 2nd-phase response • Larger proportion of secreted insulin is basal insulin • Post-meal secretory pulses are smaller in amplitude and cycles are shorter and more irregular (less coupling to glucose) Williams Textbook of Endocrinology, Edition 11.

  31. Clinical relevance of insulin synthesis Diagram representing the human preproinsulin molecule showing location of mutations causing ND. The amino acid residues in the signal peptide are indicated in green, the B chain in red, the C-peptide in orange, and the A chain in blue. The dashed circles indicate the basic residues that are the cleavage site for conversion from proinsulin to insulin. The mutations are noted in black circles together with location in the B or A chain. Stoy J et al PNAS 2007;104(38):15040-15044

  32. Clinical relevance of insulin secretion Glucokinase Bell GI et al Nature 2001;44:788-791

  33. Assays of insulin secretion and insulin resistance How do you know you have enough insulin or ineffective insulin action?

  34. Assays/Measurements • Clinical Methods • Fasting blood glucose • Oral Glucose Tolerance Test • Research Methods • Plasma insulin concentration • C-peptide concentration • HOMA/QUICKI • Hyperinsulinemic euglycemic insulin clamp • Minimal model analysis of FSIVGTT • Insulin suppression test • Insulin tolerance test • Intravenous Glucose Tolerance Test • Arginine stimulation

  35. Measures of insulin secretion and beta-cell mass • Fasting blood glucose • Fasting insulin • OGTT • C-peptide • HOMA %β • Intravenous GTT • Arginine stimulation • ?PET scan

  36. Fasting plasma glucose • Simple test • Assumes that glucose, insulin, and hepatic glucose production are in steady state • Very insensitive • Need to lose more than 40-60% of beta-cell mass before blood sugars increase in humans; in rats, need more than 70% of beta-cell mass loss. • Clinical use – one of the diagnostic criteria for diabetes

  37. Fasting insulin concentration • Simple – just a blood test • But, peripheral insulin levels are based on secretion, degradation, and distribution…. • Influenced by BMI • Does not distinguish between endogenous and exogenous insulin • So, measuring plasma insulin alone is not useful as a measure of insulin secretion (see later)

  38. Oral glucose tolerance test • 75 grams of oral glucose given; measurements of fasting glucose usually only at 0 and 120 min • False negative – take a walk/exercise during the 2 hours (unusual); not take all of the drink (makes some nauseated) • False positive – low CHO load prior to test • Can be affected by gastric emptying, gastric bypass • Clinical relevance: used as diagnostic test for diabetes – 0 min 7.0 or higher mmol/L 120 min 11.1 or higher mmol/L

  39. Stumvoll et al. show derived equations using data from OGTT has reasonable accuracy in predicting 1st phase & 2nd phase insulin release Diabetes Care, 2000; 23: 295

  40. C-peptide • Secreted in equimolar concentration to insulin • Can use a technique of C-peptide deconvolution to estimate C-peptide secretion (Eaton-Polonsky approach) – removes the substance kinetics aspect • T1/2 = 35 minutes

  41. HOMA %β • Calculation based on fasting insulin and glucose levels • = 20 x insulin (mU/L) % glucose (mmol/L) – 3.5 • Simple calculation • Caveat – uses steady state conditions to derive a dynamic situation (r=0.64 with IVGTT) Matthews DR et al Diabetologia 1985;28(7):412-419

  42. Measures of insulin resistance • Direct • Hyperinsulinemic euglycemic clamp • Insulin suppression test • Indirect • Minimal model of FSIVGTT • Simple surrogates • HOMA • QUICKI

  43. Hyperinsulinemic euglycemic clamp http://diabetesmanager.pbworks.com/w/page/17680151/Assessing%20Insulin%20Sensitivity%20and%20Resistance%20in%20Humans

  44. Hyperinsulinemic euglycemic clamp • Insulin IV run at constant rate of 5-120 mU/m2/min • BG monitored q5-10 min until steady state achieved • D20 infusion – rate adjusted to keep BGs in normal range • K infusion to avoid hypokalemia • When steady state = HGP is suppressed. Thus glucose infusion rate = glucose disposal rate • More insulin resistant means less glucose infused http://diabetesmanager.pbworks.com/w/page/17680151/Assessing%20Insulin%20Sensitivity%20and%20Resistance%20in%20Humans

  45. Hyperinsulinemic euglycemic clamp • Gold standard • It directly measures whole body glucose disposal at a given level of insulinemia under steady-state conditions • Disadvantages: • Cumbersome, labor-intensive, expensive • Feasibility limited (n should be small) • Time consuming http://diabetesmanager.pbworks.com/w/page/17680151/Assessing%20Insulin%20Sensitivity%20and%20Resistance%20in%20Humans

  46. Insulin suppression test • After overnight fast, infusion of somatostatin (250 μg/h) or octreotide (25 μg bolus followed by 0.5 μg/min) given to suppress endogenous secretion of insulin and glucagon. • Simultaneously, insulin (25 mU/m2/min) and glucose (240 mg/m2/min) are infused into same antecubital vein • In contralateral arm, blood samples for glucose and insulin taken q30 min for 2.5 h and then q10 min from 150-180 min (latter is steady-state) • SSPG (steady state plasma glucose) will be higher in IR patients http://diabetesmanager.pbworks.com/w/page/17680151/Assessing%20Insulin%20Sensitivity%20and%20Resistance%20in%20Humans

  47. Insulin suppression test • Highly reproducible • Less labor intensive and technically demanding compared to clamp but still requires more than one person and is cumbersome • Feasibility limited http://diabetesmanager.pbworks.com/w/page/17680151/Assessing%20Insulin%20Sensitivity%20and%20Resistance%20in%20Humans

  48. Indirect – Minimal model of FSIVGTT • After overnight fast, IV bolus glucose (0.3 g/kg body weight) is infused over 2 min. • IV insulin (4 mU/kg/min) is infused over 5 min beginning 20 min AFTER the IV glucose bolus. • Frequent blood samples for plasma glucose and insulin over the next 180 min • Values entered into a computer model (MINMOD) http://diabetesmanager.pbworks.com/w/page/17680151/Assessing%20Insulin%20Sensitivity%20and%20Resistance%20in%20Humans

  49. Indirect – Minimal model of FSIVGTT • Slightly less labor-intensive since there are no infusions requiring constant adjustment • Equations also can be used to calculate beta cell function (unlike the prior tests) • Not as accurate as clamp or ISTT • Can be done in larger n, potentially http://diabetesmanager.pbworks.com/w/page/17680151/Assessing%20Insulin%20Sensitivity%20and%20Resistance%20in%20Humans

More Related